CONNECT BIOPHARMA HOLD

Connect Biopharma to Participate in the Cantor Fitzgerald Global Healthcare Conference 2024

10 Sep 2024 08:00:00 By Nasdaq GlobeNewswire

Connect Biopharma Reports First Half 2024 Financial Results and Provides Business Update

05 Sep 2024 16:05:00 By Nasdaq GlobeNewswire

Connect Biopharma to Participate in the Leerink Partners I&I and Metabolism Therapeutics Forum

01 Jul 2024 08:00:00 By Nasdaq GlobeNewswire

Connect Biopharma Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

12 Jun 2024 18:03:08 By Nasdaq GlobeNewswire

Connect Biopharma Announces New Leadership and Chair of the Board of Directors

12 Jun 2024 16:15:00 By Nasdaq GlobeNewswire

Connect Biopharma Presents Late-Breaking Abstract at the American Thoracic Society 2024 International Conference on the Positive Rademikibart Data from its Global Phase 2b in Patients with Moderate-to-Severe Asthma

22 May 2024 16:05:00 By Nasdaq GlobeNewswire

Connect Biopharma to Present a Late-Breaking Abstract at the American Thoracic Society (ATS) 2024 International Conference on the Positive Results from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma

07 May 2024 06:30:00 By Nasdaq GlobeNewswire

Connect Biopharma Reports Full Year 2023 Financial Results and Provides Business Update

16 Apr 2024 16:05:00 By Nasdaq GlobeNewswire

Connect Biopharma to Participate in H.C. Wainwright 2ⁿᵈ Annual Autoimmune & Inflammatory Disease Virtual Conference

19 Mar 2024 08:30:00 By Nasdaq GlobeNewswire

Connect Biopharma Appoints Industry Veteran James Huang to Board of Directors

12 Feb 2024 16:30:00 By Nasdaq GlobeNewswire

Connect Biopharma Announces Positive Rademikibart Global Phase 2b Topline Results in Adult Patients with Moderate-to-Severe Persistent Asthma

12 Dec 2023 06:00:00 By Nasdaq GlobeNewswire

Connect Biopharma to Announce Top-Line Data from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma on December 12, 2023

11 Dec 2023 16:05:21 By Nasdaq GlobeNewswire

Connect Biopharma and Simcere Announce Exclusive Licensing and Collaboration Agreement in Greater China

21 Nov 2023 06:03:00 By Nasdaq GlobeNewswire

Connect Biopharma Announces Positive Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis

21 Nov 2023 06:00:00 By Nasdaq GlobeNewswire

Connect Biopharma to Announce Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis on November 21, 2023

20 Nov 2023 16:41:29 By Nasdaq GlobeNewswire

Connect Biopharma Reports First Half 2023 Financial Results and Provides Business Update

12 Sep 2023 16:15:09 By Nasdaq GlobeNewswire

Connect Biopharma Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement

12 Sep 2023 06:00:16 By Nasdaq GlobeNewswire

Connect Biopharma to Participate in Upcoming September Investor Conferences

24 Aug 2023 18:21:27 By Nasdaq GlobeNewswire

Connect Biopharma Presented Additional Data from its Atopic Dermatitis Pivotal Trial in China at the 2023 World Congress of Dermatology

10 Jul 2023 08:00:00 By Nasdaq GlobeNewswire

Connect Biopharma to Participate in the SVB Securities Therapeutics Forum

05 Jul 2023 16:05:00 By Nasdaq GlobeNewswire